Search results for "Tolerability"

showing 10 items of 372 documents

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a mu…

1995

Summary Purpose Vinorelbine has been demonstrated to be active against squamous cell carcinomas of the headneck (SCHNC) and lung. This multicenter phase II trial was carried out to evaluate the activity and tolerability of the combination of vinorelbine, cisplatin, and 5-fluorouracil given on an outpatient schedule in a series of 80 patients with recurrent SCHNC. Patients and methods Eighty patients with recurrent and/ or metastatic SCHNC were treated with a combination of CDDP 80 mg/m2 on day 1, 5-FU 600 mg/m2 as a 4-hour infusion on days 2-5, and vinorelbine 25 mg/m2 on days 2 + 8. This cycle was repeated every 28 days. Most patients had oral cavity, larynx, or oropharynx carcinoma (88%).…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchVinorelbineVinblastineGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansNeoplasm MetastasisAgedChemotherapybusiness.industryVinorelbineHematologyMiddle Agedmedicine.diseaseSurgeryRegimenOncologyEpidermoid carcinomaTolerabilityFluorouracilHead and Neck NeoplasmsCarcinoma Squamous CellFemaleFluorouracilCisplatinNeoplasm Recurrence Localbusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis.

2006

Although cyclosporin is effective in immunosuppression following organ transplantation and in the treatment of psoriasis, its use is limited by its side-effects, notably impaired renal function and hypertension. As SDZ IMM 125, a new derivative of the cyclosporin family, showed considerable immunosuppressive activity in experimental studies, with less effect on renal function, it was considered a potential successor to cyclosporin for both indications. In this multicentre, double-blind, placebo-controlled study, the efficacy and tolerability of 40, 100, 200 and 400 mg SDZ IMM 125 daily were studied in 59 patients with psoriasis. Patients were followed for a period of 5 weeks (4 weeks treatm…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentRenal functionCyclosporinsDermatologyPharmacologyGastroenterologyDrug Administration ScheduleDouble-Blind MethodInternal medicinePsoriasismedicineHumansPsoriasisAdverse effectBody surface areaChemotherapyDose-Response Relationship Drugbusiness.industryImmunosuppressionMiddle Agedmedicine.diseaseTolerabilityToxicityFemalebusinessImmunosuppressive AgentsFollow-Up StudiesThe British journal of dermatology
researchProduct

Safety of etanercept therapy in rheumatoid patients undergoing surgery: preliminary report

2009

This is a preliminary report on a case-series of rheumatoid patients that underwent various kinds of elective surgery but did not withdraw etanercept therapy in spite of physician advise. Elective surgery consisted of right knee surgical prosthesis, bilateral cataract, bilateral hallux valgus, right hip prosthesis, bladder stone by cystoscopy and left inguinal hernia. All the patients had a regular healing rate. During follow-up (6-12 months) no one of these patients were suffering from infective complications after surgery. According to same recent literature results, our data suggest that it is the time to value rheumatoid patient preferences through a correct information about cost-benef…

AdultMalemusculoskeletal diseasesmedicine.medical_specialtySettore MED/09 - Medicina InternaPilot ProjectsReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidPostoperative ComplicationsPatient satisfactionRheumatologyInternal medicinemedicineHumansPostoperative PeriodElective surgeryWound Healingmedicine.diagnostic_testTumor Necrosis Factor-alphabusiness.industryContraindicationsGeneral MedicineCystoscopyMiddle Agedmedicine.diseaseRheumatologySurgerySettore MED/16 - ReumatologiaTolerabilityElective Surgical ProceduresImmunoglobulin GRheumatoid arthritisFemaleBiological therapy Decompensated diabetes mellitus Etanercept Polymyalgia rheumatica Steroid therapy.businessAdverse drug reactionmedicine.drugClinical Rheumatology
researchProduct

Efficacy and pharmacological appropriateness of cinnarizine and dimenhydrinate in the treatment of vertigo and related symptoms

2021

Vertigo is not itself a disease, but rather a symptom of various syndromes and disorders that jeopardize balance function, which is essential for daily activities. It is an abnormal sensation of motion that usually occurs in the absence of motion, or when a motion is sensed inaccurately. Due to the complexity of the etiopathogenesis of vertigo, many pharmacological treatments have been tested for efficacy on vertigo. Among these drugs, cinnarizine, usually given together with dimenhydrinate, appears to be the first-line pharmacotherapy for the management of vertigo and inner ear disorders. Based on these considerations, the present non-interventional study aimed to investigate the clinical …

AdultMalepharmacological treatment of vertigomedicine.medical_specialtyCinnarizineHealth Toxicology and MutagenesisDiseasedimenhydrinateArticleCinnarizine Dimenhydrinate Dizziness Pharmacological treatment of vertigo Vertigo Adult Double-Blind Method Drug Combinations Female Histamine H1 Antagonists Humans Male Middle Aged Cinnarizine Dimenhydrinatevertigo03 medical and health sciences0302 clinical medicinePharmacotherapyDouble-Blind MethodVertigoInternal medicinemedicineotorhinolaryngologic diseasesHumans030212 general & internal medicinecinnarizine030223 otorhinolaryngologydizzinessBalance (ability)biologybusiness.industryPublic Health Environmental and Occupational HealthRMiddle Agedbiology.organism_classificationDimenhydrinateDrug CombinationsTolerabilityConcomitantHistamine H1 AntagonistsMedicineFemalebusinessmedicine.drug
researchProduct

Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer Patients

1991

Pharmacokinetics and metabolism of droloxifene, a new antiestrogenic drug, have been investigated by single- and multiple-dose studies in postmenopausal patients with advanced breast cancer. Short terminal elimination half-life, low accumulation, and improved drug tolerability are the most striking features of this safe and effective new antiestrogen. Bioequivalence of film-coated tablet, tablet, and standard solution of droloxifene has been shown. The concentrations of droloxifene and its metabolites have been determined by a highly selective HPLC method.

AdultOncologyDrugCancer Researchmedicine.medical_specialtymedia_common.quotation_subjectAdministration OralBiological AvailabilityAntineoplastic AgentsBreast NeoplasmsBioequivalenceBreast cancerPharmacokineticsInternal medicinemedicineHumansChromatography High Pressure LiquidAgedmedia_commonAged 80 and overbusiness.industryEstrogen AntagonistsCancerMiddle AgedAntiestrogenmedicine.diseaseTamoxifenOncologyTolerabilityDroloxifeneDrug EvaluationFemalebusinessHalf-LifeAmerican Journal of Clinical Oncology
researchProduct

Analysis of Safety and Tolerability Data Obtained from Over 1,500 Patients Receiving Topiramate for Migraine Prevention in Controlled Trials

2008

Objective.  Topiramate is an effective and generally well-tolerated migraine preventive therapy, as shown in three large, randomized, double-blind, placebo-controlled registration trials. Based upon efficacy/tolerability, topiramate 100 mg/day (50 mg BID) is the recommended target dose for most patients with migraine. To further assess the safety and tolerability of topiramate for migraine prevention, we analyzed safety data from 1,580 patients who participated in the three pivotal registration trials or an earlier pilot, randomized, double-blind, placebo-controlled trial. Methods.  The safety population consisted of all patients who took ≥1 dose of study medication during the double-blind …

AdultTopiramateAdolescentNauseaMigraine DisordersPopulationPhysical examinationFructosePlaceboTopiramatemedicineHumansChildAdverse effecteducationAgedRandomized Controlled Trials as Topiceducation.field_of_studymedicine.diagnostic_testbusiness.industryPatient SelectionDrug ToleranceGeneral MedicineMiddle Agedmedicine.diseaseNeuroprotective AgentsAnesthesiology and Pain MedicineTolerabilityMigraineAnesthesiaNeurology (clinical)Safetymedicine.symptombusinessmedicine.drugPain Medicine
researchProduct

Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

2020

IntroductionNatalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis (MS) treatment. Our study aimed to evaluate the effectiveness of NTZ when administered according to the extended dosing strategy compared with standard 4-weekly administration in a large Italian MS population.Materials and methodsThis retrospective multicentre study included patients with relapsing-remitting MS (RR-MS) who received NTZ administrations between the 1 June 2012 and the 15 May 2018 and were followed by the ‘Italian MS Register’. All patients with MS were stratified into two groups based on NTZ administration schedule: standard interval dosing (SID) patients who received infusions…

Adultmedicine.medical_specialtyPopulationmultiple sclerosisDrug Administration Schedule03 medical and health sciencesMultiple Sclerosis Relapsing-Remittingnatalizumab0302 clinical medicineNatalizumabDosing schedulesInternal medicinemedicineHumansImmunologic Factorsnatalizumab risk stratification multiple sclerosis safety effectivenessDosingeducationProportional Hazards ModelsRetrospective Studies030304 developmental biology0303 health scienceseducation.field_of_studyProportional hazards modelbusiness.industryMultiple sclerosisRetrospective cohort studyMiddle Agedmedicine.diseasePsychiatry and Mental healthTreatment OutcomeItalyTolerabilitySettore MED/26 - NeurologiaSurgeryNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Upper-Body Exercises With External Resistance Are Well Tolerated and Enhance Muscle Activity in People With Hemophilia

2019

Abstract Background Conventional nonresisted therapeutic exercises for people with hemophilia involve a careful, low-intensity approach to avoid injuries. Externally resisted exercise is highly efficient for increasing muscle strength in healthy adults but its feasibility for people with hemophilia remains unknown. Objective The purpose of this study was to evaluate muscle activity during upper-body rehabilitation exercises with 2 types of external resistance and without external resistance (conventional) and to examine tolerability, kinesiophobia, and possible adverse effects derived from the session. Design This was a cross-sectional study. Methods Twelve people with hemophilia A/B (11 wi…

Adultmedicine.medical_specialtyShouldermedicine.medical_treatmentElbowDeltoid curvePhysical Therapy Sports Therapy and RehabilitationElectromyographyHemophilia ABicepsUpper Extremity03 medical and health sciences0302 clinical medicinemedicineElbowHumans030212 general & internal medicineMuscle StrengthAdverse effectRehabilitationmedicine.diagnostic_testbusiness.industryElectromyographyResistance Trainingmedicine.anatomical_structureCross-Sectional StudiesTolerabilityExternal resistancePhysical therapybusiness030217 neurology & neurosurgery
researchProduct

Feasibility, safety and muscle activity during flywheel vs traditional strength training in adult patients with severe haemophilia

2021

INTRODUCTION: Eccentric training has been associated with several specific physiological adaptations. The flywheel machine is one of the easiest ways of performing eccentric overload training. However, no studies evaluated its feasibility, safety and muscle activity in patients with haemophilia (PWH).AIM: To evaluate feasibility and safety and compare muscle activity during flywheel vs weight machine knee extension exercise in severe PWH.METHODS: Eleven severe PWH [mean age of 33.5 (8.1) years] participated in this cross-sectional study after receiving prophylactic treatment. Surface electromyography (EMG) signals were recorded for the rectus femoris during the knee extension exercise perfo…

Adultmedicine.medical_specialtyStrength trainingkneeElectromyographyRectus femoris muscle030204 cardiovascular system & hematologyHemophilia AHaemophiliaFlywheel03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationflywheelHumansMedicineEccentricMuscle StrengthtolerabilityMuscle SkeletalGenetics (clinical)medicine.diagnostic_testElectromyographybusiness.industryMusclesResistance TrainingHematologyGeneral Medicinemedicine.diseaseWeight machineCross-Sectional StudieseccentricEccentric trainingFeasibility StudiesbusinessstrengthMuscle Contraction030215 immunology
researchProduct

A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder

2012

Abstract Background β-Adrenoceptor agonists are effective in animal models of bladder dysfunction, and the human bladder primarily expresses the β3 receptor subtype. Objective To evaluate the efficacy and tolerability of the highly selective and potent β3-adrenoceptor agonist solabegron in a clinical proof-of-concept study in incontinent women with overactive bladder (OAB). Design, setting, and participants This was a randomized, double-blind trial in adult women with OAB (one or more 24-h incontinence episodes and eight or more average 24-h micturitions). Interventions Solabegron 50mg ( n =88), solabegron 125mg ( n =85), or placebo ( n =85)—all twice daily—were administered. Outcome measur…

Adultmedicine.medical_specialtyTime FactorsUrologymedia_common.quotation_subjectUrinary BladderArgentinaTaiwanPlacebo-controlled studyUrologyUrinationAdrenergic beta-3 Receptor AgonistsPlaceboBenzoatesUrinationDrug Administration ScheduleSouth AfricaYoung AdultSolabegronDouble-Blind MethodRepublic of KoreamedicineHumansAgedmedia_commonAniline CompoundsUrinary Bladder Overactivebusiness.industryBiphenyl CompoundsAustraliaMiddle Agedmedicine.diseaseEuropeUrodynamicsTreatment OutcomeUrinary IncontinenceBlood pressureOveractive bladderTolerabilityAmbulatoryLinear ModelsFemalebusinessNew Zealandmedicine.drugEuropean urology
researchProduct